Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.

A study published in Frontiers in Pharmacology examines the effectiveness of a quadruplet regimen for newly diagnosed multiple myeloma (NDMM) patients. The study finds that while the quadruplet regimen is effective in the standard-risk subgroup of NDMM patients, it is not as effective in the high-risk subgroup. The study analyzes several clinical trials and concludes that triplet regimens are currently recommended as the initial treatment for NDMM, but quadruplet regimens may be a potential alternative for certain patients. The article discusses the use of quadruplet regimens for the treatment of newly diagnosed multiple myeloma (NDMM) patients. The article highlights that quadruplet regimens, which include anti-CD38 antibodies, have shown higher response rates, longer progression-free survival, and higher rates of minimal residual disease negativity compared to triplet regimens. However, the data on overall survival is limited, and the cost-effectiveness of quadruplet regimens needs to be considered, especially in developing countries. For high-risk NDMM patients, the efficacy of quadruplet regimens is still uncertain, and more evidence is needed to support their use. Overall, careful consideration is recommended when choosing quadruplet regimens as the first-line treatment for NDMM patients. This document is a list of references cited in an article published in Frontiers in Pharmacology. The article discusses various treatment regimens and therapies for newly diagnosed multiple myeloma, a type of cancer. The references include studies [Extracted from the article]